Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.06 HKD | +1.00% | +4.13% | -16.67% |
Business Summary
- drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%);
- vitamin C (10.1%);
- antibiotics (6.2%);
- other (5%): including anhydrous and raw caffeine.
Net sales are distributed geographically as follows: China (82.8%), Asia (7.2%), Europe (4.6%), the Americas (4.4%) and others (1%).
Number of employees: 23,500
Sales per Business
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Finished Drugs
79.3
%
| 22,681 | 81.4 % | 24,520 | 79.3 % | +8.11% |
Vitamin C
8.2
%
| 2,149 | 7.7 % | 2,529 | 8.2 % | +17.68% |
Functional Food and Others
6.4
%
| 1,366 | 4.9 % | 1,966 | 6.4 % | +43.89% |
Antibiotics and Others
6.2
%
| 1,670 | 6.0 % | 1,922 | 6.2 % | +15.07% |
Sales per region
HKD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
China
84.5
%
| 24,289 | 87.2 % | 26,139 | 84.5 % | +7.62% |
Other Asian Regions
5.6
%
| 1,475 | 5.3 % | 1,736 | 5.6 % | +17.71% |
Americas
4.9
%
| 1,159 | 4.2 % | 1,510 | 4.9 % | +30.23% |
Europe
4.1
%
| 700 | 2.5 % | 1,268 | 4.1 % | +81.08% |
Others
0.9
%
| 244 | 0.9 % | 284 | 0.9 % | +16.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Cui Long Zhang
CEO | Chief Executive Officer | 55 | 95-12-31 |
Dong Chen Cai
CHM | Chairman | 70 | 97-12-31 |
Hao Jiang
BRD | Director/Board Member | 41 | 20-07-31 |
Zhen Guo Wang
BRD | Director/Board Member | 54 | 12-01-19 |
Huai Yu Wang
BRD | Director/Board Member | 61 | 09-12-31 |
Wei Dong Pan
BRD | Director/Board Member | 55 | 05-12-31 |
Jin Xu Wang
PRN | Corporate Officer/Principal | 53 | 13-06-09 |
Tai On Lo
SEC | Corporate Secretary | 69 | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dong Chen Cai
CHM | Chairman | 70 | 97-12-31 |
Wei Dong Pan
BRD | Director/Board Member | 55 | 05-12-31 |
Bo Wang
BRD | Director/Board Member | 64 | 12-12-20 |
Cheuk Kin Law
BRD | Director/Board Member | 61 | 21-03-07 |
Kin Man Chak
BRD | Director/Board Member | 58 | 04-12-31 |
Zhen Guo Wang
BRD | Director/Board Member | 54 | 12-01-19 |
Chun Lei Li
BRD | Director/Board Member | - | 17-12-11 |
Cui Long Zhang
CEO | Chief Executive Officer | 55 | 95-12-31 |
Qingxi Wang
BRD | Director/Board Member | 58 | 18-08-19 |
Hao Jiang
BRD | Director/Board Member | 41 | 20-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,922,719,732 | 8,371,200,069 ( 70.21 %) | 0 | 70.21 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
131,267,092 | 69.84% | 672,004,813 $ | |
51,241,785 | 46.32% | 51,723,458 $ |
Company contact information
CSPC Pharmaceutical Group Ltd.
No. 226 Huanghe Street
050035, Shijiazhuang
+86 31 1870 37015
http://www.cspc.com.hkSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 9.07B | |
+25.46% | 659B | |
+25.38% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.13% | 215B | |
+2.93% | 210B | |
-7.65% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- 1093 Stock
- Company CSPC Pharmaceutical Group Ltd.